Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
CORV was delisted on the 26th of May, 2020.
24 hedge funds and large institutions have $60M invested in Correvio Pharma Corp. Ordinary Shares (Canada) in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
57% more capital invested
Capital invested by funds: $38.3M → $60M (+$21.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 25 → 24 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
71% less call options, than puts
Call options by funds: $23K | Put options by funds: $78K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$1.14M |
| 2 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$326K |
| 3 |
Renaissance Technologies
New York
|
+$200K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$88.2K |
| 5 |
Morgan Stanley
New York
|
+$44.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.42M |
| 2 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$44K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$37.8K |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$35K |
| 5 |
LPL Financial
San Diego,
California
|
-$29K |
CORV Hedge Fund Activity: Q2 2018 in Review
24 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) for Q2 2018, worth a combined $60M — up 57% from $38.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CORV and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 8 added.
The largest buyer was Westfield Capital Management, adding an estimated $1.14M. The largest seller was Stonepine Capital Management, cutting an estimated $3.42M.
- 24 institutional investors held Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) as of Q2 2018, down from 25 in Q1 2018.
- Funds reported $60M of Correvio Pharma Corp. Ordinary Shares (Canada) stock for Q2 2018, up 57% quarter-over-quarter.
- 4 funds opened new Correvio Pharma Corp. Ordinary Shares (Canada) positions in Q2 2018 and 5 closed out, a net change of -1 holder.
- The largest Correvio Pharma Corp. Ordinary Shares (Canada) buyer in Q2 2018 was Westfield Capital Management, an estimated $1.14M added.
- The largest Correvio Pharma Corp. Ordinary Shares (Canada) seller in Q2 2018 was Stonepine Capital Management, an estimated $3.42M sold.
Based on aggregated 13F filings for Q2 2018.